Mesodermal cell/mesoblast sarcoma - spindle cell |
Skin |
None (spontaneous) |
FVB/N
inbred
|
|
|
|
0 |
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma - spindle cell |
Skin |
Chemical/Drug
phorbol 12-myristate 13-acetate (phorbol ester) (PMA)
|
FVB/N
inbred
|
|
|
|
0 |
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma - spindle cell |
Skin |
Chemical/Drug
retinoic acid (RA)
|
FVB/N
inbred
|
|
|
|
0 |
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma - spindle cell |
Skin |
Chemical/Drug
phorbol 12-myristate 13-acetate (phorbol ester) (PMA)
retinoic acid (RA)
|
FVB/N
inbred
|
|
|
|
0 |
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma - spindle cell |
Skin |
Other
wounding
|
FVB/N
inbred
|
|
|
|
0 |
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma - spindle cell |
Skin |
None (spontaneous) |
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
|
|
|
0 |
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma - spindle cell |
Skin |
Chemical/Drug
phorbol 12-myristate 13-acetate (phorbol ester) (PMA)
|
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
|
|
|
observed |
Lymph node |
|
Summary
|
Mesodermal cell/mesoblast sarcoma - spindle cell |
Skin |
Chemical/Drug
retinoic acid (RA)
|
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
|
|
|
0 |
|
|
Summary
|
Mesodermal cell/mesoblast sarcoma - spindle cell |
Skin |
Chemical/Drug
phorbol 12-myristate 13-acetate (phorbol ester) (PMA)
retinoic acid (RA)
|
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
|
|
|
observed |
Lymph node |
|
Summary
|
Mesodermal cell/mesoblast sarcoma - spindle cell |
Skin |
Other
wounding
|
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
|
observed |
|
|
Lymph node |
|
Summary
|
Skin hyperplasia |
Skin |
Chemical/Drug
phorbol 12-myristate 13-acetate (phorbol ester) (PMA)
|
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
|
|
|
observed |
|
|
Summary
|
Skin hyperplasia |
Skin |
Chemical/Drug
phorbol 12-myristate 13-acetate (phorbol ester) (PMA)
|
FVB/N
inbred
|
|
|
|
observed |
|
|
Summary
|
Skin keratoacanthoma |
Skin |
Chemical/Drug
phorbol 12-myristate 13-acetate (phorbol ester) (PMA)
|
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
|
|
|
observed |
|
|
Summary
|
Skin papilloma |
Skin |
Other
wounding
|
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
observed |
observed - 100 |
|
|
|
|
Summary
|
Skin papilloma |
Skin |
None (spontaneous) |
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
0 |
|
|
0 |
|
|
Summary
|
Skin papilloma |
Skin |
None (spontaneous) |
FVB/N
inbred
|
|
|
|
0 |
|
|
Summary
|
Skin papilloma |
Skin |
Chemical/Drug
phorbol 12-myristate 13-acetate (phorbol ester) (PMA)
|
FVB/N
inbred
|
|
|
|
0 |
|
|
Summary
|
Skin papilloma |
Skin |
Chemical/Drug
retinoic acid (RA)
|
FVB/N
inbred
|
|
|
|
0 |
|
|
Summary
|
Skin papilloma |
Skin |
Chemical/Drug
phorbol 12-myristate 13-acetate (phorbol ester) (PMA)
retinoic acid (RA)
|
FVB/N
inbred
|
|
|
|
0 |
|
|
Summary
|
Skin papilloma |
Skin |
Other
wounding
|
FVB/N
inbred
|
|
|
|
0 |
|
|
Summary
|
Skin papilloma |
Skin |
Chemical/Drug
phorbol 12-myristate 13-acetate (phorbol ester) (PMA)
|
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
|
|
|
97 |
|
|
Summary
|
Skin papilloma |
Skin |
Chemical/Drug
retinoic acid (RA)
|
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
|
|
|
0 |
|
|
Summary
|
Skin papilloma |
Skin |
Chemical/Drug
phorbol 12-myristate 13-acetate (phorbol ester) (PMA)
retinoic acid (RA)
|
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
|
|
|
25 - 42 |
|
|
Summary
|
Skin squamous cell carcinoma |
Skin |
None (spontaneous) |
FVB/N
inbred
|
|
|
|
0 |
|
|
Summary
|
Skin squamous cell carcinoma |
Skin |
Chemical/Drug
phorbol 12-myristate 13-acetate (phorbol ester) (PMA)
|
FVB/N
inbred
|
|
|
|
0 |
|
|
Summary
|
Skin squamous cell carcinoma |
Skin |
Chemical/Drug
retinoic acid (RA)
|
FVB/N
inbred
|
|
|
|
0 |
|
|
Summary
|
Skin squamous cell carcinoma |
Skin |
Chemical/Drug
phorbol 12-myristate 13-acetate (phorbol ester) (PMA)
retinoic acid (RA)
|
FVB/N
inbred
|
|
|
|
0 |
|
|
Summary
|
Skin squamous cell carcinoma |
Skin |
Other
wounding
|
FVB/N
inbred
|
|
|
|
0 |
|
|
Summary
|
Skin squamous cell carcinoma |
Skin |
None (spontaneous) |
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
|
|
|
0 |
|
|
Summary
|
Skin squamous cell carcinoma |
Skin |
Chemical/Drug
phorbol 12-myristate 13-acetate (phorbol ester) (PMA)
|
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
|
|
|
observed |
Lymph node |
|
Summary
|
Skin squamous cell carcinoma |
Skin |
Chemical/Drug
retinoic acid (RA)
|
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
|
|
|
0 |
|
|
Summary
|
Skin squamous cell carcinoma |
Skin |
Chemical/Drug
phorbol 12-myristate 13-acetate (phorbol ester) (PMA)
retinoic acid (RA)
|
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
|
|
|
observed |
Lymph node |
|
Summary
|
Skin squamous cell carcinoma |
Skin |
Other
wounding
|
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
|
observed |
|
|
Lymph node |
|
Summary
|
Spleen hyperplasia |
Spleen |
None (spontaneous) |
FVB/NTac-Tg(Hba-x-v-Ha-ras)TG.ACLed
transgenic
|
|
|
|
observed |
|
|
Summary
|